(19)
(11) EP 1 337 560 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.10.2008 Bulletin 2008/42

(45) Mention of the grant of the patent:
27.08.2008 Bulletin 2008/35

(21) Application number: 01997506.9

(22) Date of filing: 22.11.2001
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)
A61K 38/17(2006.01)
A61P 37/00(2006.01)
A61K 39/395(2006.01)
G01N 33/68(2006.01)
 C07K 16/28(2006.01)
A61K 31/70(2006.01)
A61P 31/00(2006.01)
A61P 25/28(2006.01)
(86) International application number:
PCT/CA2001/001641
(87) International publication number:
WO 2002/042332 (30.05.2002 Gazette 2002/22)

(54)

TRUNCATED CD200

VERKÜRZTES CD200

CD200 TRONQUEE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.11.2000 US 252424 P

(43) Date of publication of application:
27.08.2003 Bulletin 2003/35

(73) Proprietor: Trillium Therapeutics Inc.
Toronto, Ontario M9W 4Y9 (CA)

(72) Inventor:
  • GORCZYNSKI, Reginald, M.
    Willowdale, Ontario M2R 2K6 (CA)

(74) Representative: Harrison Goddard Foote 
Belgrave Hall Belgrave Street
Leeds LS2 8DD
Leeds LS2 8DD (GB)


(56) References cited: : 
WO-A-02/11762
 WO-A-99/24565
   
  • GORCZYNSKI R M ET AL: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 AUG 1999, vol. 163, no. 3, 1 August 1999 (1999-08-01), pages 1654-1660, XP002222032 ISSN: 0022-1767
  • GORCZYNSKI R M ET AL: "Anti-rat OX-2 blocks increased small intestinal transplant survival after portal vein immunization." TRANSPLANTATION PROCEEDINGS, vol. 31, no. 1-2, February 1999 (1999-02), pages 577-578, XP002222033 XVIIth World Congress of the Transplantation Society;Montreal, Quebec, Canada; July 12-17, 1998 ISSN: 0041-1345
  • DATABASE EMBL [Online] 9 February 1996 (1996-02-09) TAKEDA J: "similar to ox-2 cell surface antigen" Database accession no. D82639 XP002222034
  • DATABASE EMBL [Online] 2 November 1999 (1999-11-02) LEE N H ET AL.: "EST291980 Normalized rat ovary, Bento Soares Rattus sp. cDNA clone RGICL47 5' end similar to cell surface protein MRC OX-2, mRNA sequence" Database accession no. AW141865 XP002222035
  • DATABASE EMBL [Online] 2 July 2000 (2000-07-02) KONNO H ET AL.: "Mus musculus 10 days neonate cortex cDNA, RIKEN full-length enriched library, clone:A830086N06, 3' end partial sequence, similar to ddbj:AF004023 Mus musculus cell surface molecule OX-2 mRNA" Database accession no. BB274162 XP002222036
  • STEURER W ET AL: "EX VIVO COATING OF ISLET CELL ALLOGRAFTS WITH MURINE CTLA4/FC PROMOTES GRAFT TOLERANCE" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 155, no. 3, 1 August 1995 (1995-08-01), pages 1165-1174, XP002031135 ISSN: 0022-1767
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).